In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Clifton L RicañaEmory University School of Medicine, Department of Pediatrics, Laboratory of Biochemical Pharmacology, Center for ViroScience & Cure, Atlanta, GA 30322, USA.ORCID 0000-0002-9733-9136 Savannah G BrancatoEmory University School of Medicine, Department of Pediatrics, Laboratory of Biochemical Pharmacology, Center for ViroScience & Cure, Atlanta, GA 30322, USA.ORCID 0000-0002-9267-500X Carolyn M HighlandCornell University, Department of Molecular Biology and Genetics, Ithaca, NY 14853, USA.ORCID 0000-0003-4029-0113 Fatemeh EkbataniamiriCornell University, Plant Pathology and Plant-Microbe Biology Section, Ithaca, NY 14853, USA.ORCID 0000-0001-5746-6627 Krisztina AmbrusEmory University School of Medicine, Department of Pediatrics, Laboratory of Biochemical Pharmacology, Center for ViroScience & Cure, Atlanta, GA 30322, USA.ORCID 0009-0001-9891-3152 Mia FaerchCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98105, USA.ORCID 0000-0001-8578-645X Bruce E TorbettCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98105, USA.ORCID 0000-0003-4995-1694 Juan R PerillaUniversity of Delaware, Department of Chemistry & Biochemistry, Newark, DE 19716, USA.ORCID 0000-0003-1171-6816 Robert A DickEmory University School of Medicine, Department of Pediatrics, Laboratory of Biochemical Pharmacology, Center for ViroScience & Cure, Atlanta, GA 30322, USA.ORCID 0000-0003-3693-2531 Funding
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Alan N. Engelman · 2022 to 2026
$36.7MProject 3. IntegrationU54AI170791 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGELA M. GRONENBORN · 2022 to 2026
$30.6MPacific Northwest Center for Cryo-EM: Equipment SupplementR24GM154185 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI James E Evans, CLAUDIA SUSANA LOPEZ · 2024 to 2026
$21.5MStructural Virology of Tripartite Motif ProteinsR37AI150479 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Owen Pornillos · 2022 to 2026
$3.0MDetermining the molecular mechanisms of HIV-1 maturationR01AI178846 · NIAID · UNIVERSITY OF DELAWARE · PI Juan Roberto Perilla Jimenez · 2023 to 2026
$2.3MRetrovirus Structure and Assembly with Inositol PhosphatesR01AI147890 · NIAID · EMORY UNIVERSITY · PI DICK, ROBERT A · 2019 to 2022
$1.6MStructural interrogation of the HIV-1 virion and the mechanism of the capsid targeting compound LenacapavirR56AI189254 · NIAID · EMORY UNIVERSITY · PI DICK, ROBERT A · 2025 to 2025
$654kNIAID NIH HHS R01 AI147890NIAID NIH HHS R01 AI178846NIAID NIH HHS R37 AI150479NIAID NIH HHS R56 AI189254NIAID NIH HHS U54 AI170791NIAID NIH HHS U54 AI170855NIGMS NIH HHS R24 GM154185
6 · The paper itselfAbstract
The HIV-1 capsid effector Lenacapavir (LEN) acts by disrupting the early (reverse transcription and nuclear entry) and late (assembly and maturation) stages of the viral lifecycle. The early stage requires an intact Capsid consisting of a lattice of capsid protein (CA) hexamers and pentamers. Phenylalanine-Glycine (FG) containing nuclear pore proteins interact with Capsid hexamers at their FG pockets, facilitating nuclear entry. Disruption of Capsid lattice stability, or competitive binding to the FG pocket, by LEN blocks infection. Here, we provide insight into the effects of LEN on the late stage. Using a combination of cryo-EM structure determination,
Indexed as
CryoEMHIV-1LenacapavirSunlencaYeztugo
Identifiers
PMID41867786
PMCPMC13001338
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390